Journal of Medicinal Chemistry · 2020 · 87 citations · 51 references
MedicineOncologyPharmacologyCancer PharmacologyImmunoregulationMolecular OncologyCancer ImmunotherapyProtein DomainsProtein Interaction DomainsBromodomain InhibitionBromodomain ProteinsProtein Kinase Inhibitors
Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins. They have shown profound efficacy in vitro and in vivo in oncology and immunomodulatory models, and a number of them are currently in clinical trials where significant safety signals have been reported. It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity. This article discloses the in vitro and cellular activity profiles of GSK789, a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.
51
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text